Celcuity Director Sells $2.4 Million in Shares via Indirect Transaction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Should l Buy CELC?
Source: Fool
- Indirect Share Sale: Director David Dalvey reported an indirect sale of 20,000 shares of Celcuity through Brightstone Venture Capital Fund for approximately $2.4 million, indicating a need for liquidity amid a strong stock performance.
- Holding Proportion Change: This transaction reduced Dalvey's indirect holdings from 110,000 to 90,000 shares, representing 18.18% of his total holdings, reflecting a trend of divestment in the company.
- Market Performance Review: Celcuity's stock has delivered a remarkable 933% total return over the past year, and Dalvey's sale occurs against this backdrop, potentially to lock in profits and manage future uncertainties.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan adopted by Brightstone, indicating that Dalvey's transaction was prearranged to avoid insider trading implications, reminding investors to focus on the company's fundamentals rather than solely on insider trading activities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 106.50 USD with a low forecast of 94.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 104.280
Low
94.00
Averages
106.50
High
126.00
Current: 104.280
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Director Sells $2.4 Million in Shares via Indirect Transaction
- Indirect Share Sale: Director David Dalvey reported an indirect sale of 20,000 shares of Celcuity through Brightstone Venture Capital Fund for approximately $2.4 million, indicating a need for liquidity amid a strong stock performance.
- Holding Proportion Change: This transaction reduced Dalvey's indirect holdings from 110,000 to 90,000 shares, representing 18.18% of his total holdings, reflecting a trend of divestment in the company.
- Market Performance Review: Celcuity's stock has delivered a remarkable 933% total return over the past year, and Dalvey's sale occurs against this backdrop, potentially to lock in profits and manage future uncertainties.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan adopted by Brightstone, indicating that Dalvey's transaction was prearranged to avoid insider trading implications, reminding investors to focus on the company's fundamentals rather than solely on insider trading activities.
See More
Celcuity to Participate in Biotech Summit 2026
- Biotech Summit Participation: Celcuity Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, showcasing its latest advancements in oncology treatments and enhancing its visibility in the biotech industry.
- CEO Interview Schedule: CEO Brian Sullivan is set to engage in a fireside chat at 9:30 a.m. on February 11, where he is expected to discuss the company's strategic direction in targeted therapies, bolstering investor confidence in its growth trajectory.
- Clinical Trial Progress: Celcuity's lead therapeutic candidate, gedatolisib, is involved in multiple clinical trials, including VIKTORIA-1, which has completed enrollment, and VIKTORIA-2, which is currently enrolling, demonstrating the company's ongoing commitment and potential in cancer treatment.
- Unique Drug Mechanism: Gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor, has a mechanism of action that significantly differs from existing therapies, potentially offering new treatment options for various solid tumor patients and further solidifying the company's competitive position in the biopharmaceutical market.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib, Target Action Date July 17, 2026
- FDA Priority Review: Celcuity announced that its lead drug gedatolisib has received FDA priority review, marking a significant advancement in the biotech sector and potentially accelerating market entry.
- Target Approval Date: The FDA has set July 17, 2026, as the target action date for the new drug application for gedatolisib, providing a clear timeline for Celcuity's commercialization strategy.
- Clinical Trial Data Support: According to last month's data update, gedatolisib demonstrated a median progression-free survival of up to 12.4 months in the VIKTORIA-1 clinical trial, indicating its efficacy and favorable safety profile in combination therapy, thereby enhancing the likelihood of FDA approval.
- Revenue Potential Outlook: Celcuity outlines a peak revenue potential of $2.5 billion to $3 billion for gedatolisib, which is expected to attract more investor interest as the company accelerates its launch preparations.
See More
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib with Goal Date of July 17, 2026
- NDA Acceptance: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA, targeting hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, showcasing the company's potential in oncology treatment.
- Priority Review Granted: The FDA has granted Priority Review status to the application, setting a goal date of July 17, 2026, indicating the agency's recognition of the drug's significance and potential market value.
- Clinical Trial Basis: The submission is based on data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial, demonstrating the drug's efficacy in clinical research and laying the groundwork for future market introduction.
- Market Reaction: Despite the positive FDA news, Celcuity shares fell over 2% in pre-market trading, reflecting cautious investor sentiment regarding the drug's market prospects, which may impact investor confidence.
See More
Celcuity Inc. Receives FDA Priority Review for Gedatolisib with PDUFA Goal Date of July 17, 2026
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted for Priority Review by the FDA, with a PDUFA goal date of July 17, 2026, marking a significant milestone in providing a much-needed treatment option for patients with HR+/HER2- advanced breast cancer.
- Clinical Data Support: The application is based on clinical data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, demonstrating gedatolisib's efficacy in inhibiting the PI3K/AKT/mTOR pathway, which could potentially change existing treatment paradigms and enhance market competitiveness.
- Multi-Target Mechanism Advantage: As a multi-target PI3K/AKT/mTOR inhibitor, gedatolisib offers comprehensive blockade of the PAM pathway, showing greater potency and cytotoxicity compared to single-target inhibitors, which may lead to improved clinical outcomes.
- Future Clinical Trial Plans: Celcuity is conducting multiple clinical trials, including VIKTORIA-2 and CELC-G-201, aimed at further validating the efficacy and safety of gedatolisib, which is expected to lay the groundwork for the company's future commercialization efforts.
See More
Celcuity Director Sells $2.4 Million in Shares via Indirect Transaction
- Indirect Share Sale: Director David Dalvey reported an indirect sale of 20,000 shares of Celcuity through Brightstone Venture Capital Fund for approximately $2.4 million, indicating a need for liquidity amid a strong stock performance.
- Holding Proportion Change: This transaction reduced Dalvey's indirect holdings from 110,000 to 90,000 shares, representing 18.18% of his total holdings, reflecting a trend of divestment in the company.
- Market Performance Review: Celcuity's stock has delivered a remarkable 933% total return over the past year, and Dalvey's sale occurs against this backdrop, potentially to lock in profits and manage future uncertainties.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan adopted by Brightstone, indicating that Dalvey's transaction was prearranged to avoid insider trading implications, reminding investors to focus on the company's fundamentals rather than solely on insider trading activities.
See More
Celcuity to Participate in Biotech Summit 2026
- Biotech Summit Participation: Celcuity Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, showcasing its latest advancements in oncology treatments and enhancing its visibility in the biotech industry.
- CEO Interview Schedule: CEO Brian Sullivan is set to engage in a fireside chat at 9:30 a.m. on February 11, where he is expected to discuss the company's strategic direction in targeted therapies, bolstering investor confidence in its growth trajectory.
- Clinical Trial Progress: Celcuity's lead therapeutic candidate, gedatolisib, is involved in multiple clinical trials, including VIKTORIA-1, which has completed enrollment, and VIKTORIA-2, which is currently enrolling, demonstrating the company's ongoing commitment and potential in cancer treatment.
- Unique Drug Mechanism: Gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor, has a mechanism of action that significantly differs from existing therapies, potentially offering new treatment options for various solid tumor patients and further solidifying the company's competitive position in the biopharmaceutical market.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib, Target Action Date July 17, 2026
- FDA Priority Review: Celcuity announced that its lead drug gedatolisib has received FDA priority review, marking a significant advancement in the biotech sector and potentially accelerating market entry.
- Target Approval Date: The FDA has set July 17, 2026, as the target action date for the new drug application for gedatolisib, providing a clear timeline for Celcuity's commercialization strategy.
- Clinical Trial Data Support: According to last month's data update, gedatolisib demonstrated a median progression-free survival of up to 12.4 months in the VIKTORIA-1 clinical trial, indicating its efficacy and favorable safety profile in combination therapy, thereby enhancing the likelihood of FDA approval.
- Revenue Potential Outlook: Celcuity outlines a peak revenue potential of $2.5 billion to $3 billion for gedatolisib, which is expected to attract more investor interest as the company accelerates its launch preparations.
See More
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib with Goal Date of July 17, 2026
- NDA Acceptance: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA, targeting hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, showcasing the company's potential in oncology treatment.
- Priority Review Granted: The FDA has granted Priority Review status to the application, setting a goal date of July 17, 2026, indicating the agency's recognition of the drug's significance and potential market value.
- Clinical Trial Basis: The submission is based on data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial, demonstrating the drug's efficacy in clinical research and laying the groundwork for future market introduction.
- Market Reaction: Despite the positive FDA news, Celcuity shares fell over 2% in pre-market trading, reflecting cautious investor sentiment regarding the drug's market prospects, which may impact investor confidence.
See More
Celcuity Inc. Receives FDA Priority Review for Gedatolisib with PDUFA Goal Date of July 17, 2026
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted for Priority Review by the FDA, with a PDUFA goal date of July 17, 2026, marking a significant milestone in providing a much-needed treatment option for patients with HR+/HER2- advanced breast cancer.
- Clinical Data Support: The application is based on clinical data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, demonstrating gedatolisib's efficacy in inhibiting the PI3K/AKT/mTOR pathway, which could potentially change existing treatment paradigms and enhance market competitiveness.
- Multi-Target Mechanism Advantage: As a multi-target PI3K/AKT/mTOR inhibitor, gedatolisib offers comprehensive blockade of the PAM pathway, showing greater potency and cytotoxicity compared to single-target inhibitors, which may lead to improved clinical outcomes.
- Future Clinical Trial Plans: Celcuity is conducting multiple clinical trials, including VIKTORIA-2 and CELC-G-201, aimed at further validating the efficacy and safety of gedatolisib, which is expected to lay the groundwork for the company's future commercialization efforts.
See More
